Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Deloitte
Chubb
Julphar
Chinese Patent Office
Medtronic
Boehringer Ingelheim
Teva

Generated: June 24, 2018

DrugPatentWatch Database Preview

Bristol Myers Company Profile

« Back to Dashboard

Summary for Bristol Myers
International Patents:447
US Patents:17
Tradenames:71
Ingredients:61
NDAs:83
Patent Litigation for Bristol Myers: See patent lawsuits for Bristol Myers

Drugs and US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb METAGLIP glipizide; metformin hydrochloride TABLET;ORAL 021460-003 Oct 21, 2002 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb GLUCOPHAGE metformin hydrochloride TABLET;ORAL 020357-002 Mar 3, 1995 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers QUESTRAN LIGHT cholestyramine POWDER;ORAL 019669-001 Dec 5, 1988 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-001 Oct 31, 2000 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb MONOPRIL fosinopril sodium TABLET;ORAL 019915-004 Mar 28, 1995 4,384,123 ➤ Try a Free Trial
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-002 Oct 31, 2000 5,254,539*PED ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 5,811,423 ➤ Try a Free Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-003 Jun 24, 2003 4,346,227*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28

Non-Orange Book US Patents for Bristol Myers

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,979,694 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
8,470,854 Lactam-containing compounds and derivatives thereof as factor XA inhibitors ➤ Try a Free Trial
7,338,963 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
7,189,854 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bristol Myers Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0046 Belgium ➤ Try a Free Trial PRODUCT NAME: DOXORUBICIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/96/011/001 19960624
60026 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
00617 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
90002-8 Sweden ➤ Try a Free Trial PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REG. NO/DATE: EU/1/15/1025 20150715
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Boehringer Ingelheim
Fish and Richardson
Daiichi Sankyo
Medtronic
McKinsey
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.